Rigel Pharmaceuticals, Inc. Forecast, price target & analysts
Rigel Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Rigel Pharmaceuticals, Inc. Classifications & Recommendation:
Rigel Pharmaceuticals, Inc. Price Target
| Target Price | $33.74 |
| Price | $20.12 |
| Potential |
67.70%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Rigel Pharmaceuticals, Inc. 2026 .
The average Rigel Pharmaceuticals, Inc. target price is $33.74.
This is
67.70%
register free of charge
$57.00
183.30%
register free of charge
$20.45
1.64%
register free of charge
|
|
| A rating was issued by 6 analysts: 2 Analysts recommend Rigel Pharmaceuticals, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rigel Pharmaceuticals, Inc. stock has an average upside potential 2026 of
67.70%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 179.28 | 216.75 |
| 53.39% | 20.90% | |
| EBITDA Margin | 14.74% | 25.40% |
| 189.48% | 72.36% | |
| Net Margin | 9.87% | 17.20% |
| 144.82% | 74.30% |
6 Analysts have issued a sales forecast Rigel Pharmaceuticals, Inc. 2025 . The average Rigel Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Rigel Pharmaceuticals, Inc. EBITDA forecast 2025. The average Rigel Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Rigel Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Rigel Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.99 | 2.09 |
| 168.75% | 111.11% | |
| P/E | 9.64 | |
| EV/Sales | 1.59 |
6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast for earnings per share. The average Rigel Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rigel Pharmaceuticals, Inc....
Current Rigel Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 22 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 23 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 22 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
